Switch to:
Biomarin Pharmaceutical Inc (NAS:BMRN)
Research and Development
$663 Mil (TTM As of Sep. 2016)

This is the expense the company spent on research and development. Biomarin Pharmaceutical Inc's research and development for the three months ended in Sep. 2016 was $161 Mil. Its research and development for the trailing twelve months (TTM) ended in Sep. 2016 was $663 Mil.


Definition

This is the expense the company spent on research and development.

Biomarin Pharmaceutical Inc Research & Development for the trailing twelve months (TTM) ended in Sep. 2016 was 176.118 (Dec. 2015 ) + 158.793 (Mar. 2016 ) + 167.039 (Jun. 2016 ) + 160.831 (Sep. 2016 ) = $663 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Biomarin Pharmaceutical Inc Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
Research & Development 677993115147214302355462635

Biomarin Pharmaceutical Inc Quarterly Data

Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16
Research & Development 108126142142158159176159167161
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK